The FMHR traders, and John Spallanzani, GFI Group, debate the trade on pharma stocks after CNBC's Jim Cramer suggests there are positive signs for the sector. » Read More
The “Halftime Report” experts discuss.
In a story April 28 about an Abbott Laboratories plan to buy St. Jude Medical, The Associated Press reported erroneously the deal's value. Abbott Laboratories will spend $25 billion to buy St. Jude Medical, not $19.3 billion. Abbott Labs to spend $25 billion to buy St. Jude Medical.
Most companies are feeling all right about their business, but weak sales growth is making M&A synergies attractive, Roger Altman says.
Diagnostic test maker Alere said it has rejected a request by Abbott Laboratories to terminate the $5.8 billion deal to buy Alere for a breakup fee.
St. Jude Medical Inc., up $15.84 to $77.79. GNC Holdings Inc., down $10.28 to $25.32. AbbVie Inc., up 50 cents to $61.20.
CNBC's David Faber looks at the mega-deals going down including Abbott Labs buying St. Jude, Sanofi's hostile bid for Medivation and Comcast's all-cash buy of DreamWorks Animation.
Discussing the M&A space for biotech and health care with Les Funtleyder, Asset Management Portfolio Manager at ESquared, and Michael Yee, BioTech Analyst at RBC Capital Markets
Abbott Labs said it agreed to St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
CNBC contributor and Former Medtronic CEO Bill George reacts to the merger between St. Jude Medical and Abbott Labs.
Abbott Labs Chairman and CEO Miles White, explains the timing behind the merger with St. Jude Medical.
Abbott Labs Chairman and CEO Miles White discusses whether the company looked at inversion, after announcing a deal to buy St. Jude Medical.
Abbott Labs is buying St. Jude Medical for $25 billion. Abbott Labs Chairman and CEO Miles White, discusses the fit for both companies.
CNBC's David Faber reports Abbott Labs is agreeing to buy St. Jude Medical in a cash and stock deal. CNBC's Jim Cramer, weighs in.
Some of the names on the move ahead of the open.
Abbott Laboratories will spend $19.3 billion to buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's stake in cardiovascular care. The combined company will offer devices in nearly every area of cardiovascular care, competing directly with industry leaders Medtronic Inc. and Boston Scientific Corp. It noted...
Dane Leone, BTIG analyst, discusses Abbott Labs' $25 billion dollar bid for St. Jude for about $85 per share.
Abbott Laboratories is making a $25 billion bid for St. Jude, reports the "Squawk Box" crew.
NEW YORK— U.S. stocks took their biggest loss in three weeks on Thursday after a late sell-off. Tech stocks, which rose early on thanks to earnings gains from Facebook and PayPal, slumped after billionaire investor Carl Icahn disclosed that he'd sold his stake in Apple. Investors were surprised the Bank of Japan decided not to take further action to stimulate that...
Jim Cramer explains what to watch ahead of the open including Abbott Labs' quarterly report.
U.S. stock index futures indicated a flat open with investors digesting the results of the New York primaries.